Renal dysfunction in allogeneic hematopoietic cell transplantation

Chirag R. Parikh(College of Medicine & JNM Hospital), Robert W. Schrier(University of Denver), Tevfik Ecder, Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Aïcha Mérouani(University of Colorado Health), Jeremy Taylor(University of Colorado Denver), Peter A. McSweeney(Mesoblast (United States)), Roy B. Jones(The University of Texas MD Anderson Cancer Center), Vicki Slat-Vasquez(University of Colorado Denver), Scott I. Bearman(University of Washington), Didem Korular(University of Colorado Denver)
Kidney International
August 1, 2002
10.1046/j.1523-1755.2002.00455.x
Cited by 153

Related Papers

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
Tolvaptan, a Selective Oral Vasopressin V <sub>2</sub> -Receptor Antagonist, for Hyponatremia
|New England Journal of Medicine|2006|1.2k